Drug-Drug Interactions in HIV/HCV Coinfection

Experts discuss the management of drug-drug interactions in patients receiving treatment for HIV and HCV coinfection.

HCV Racial Disparities and Treatment Outcomes

Racial disparities in HCV treatment outcomes can be partially explained by the differences in underlying immune/genetic characteristics of patients.

Preventing HCV With Needle/Syringe Programs

Needle/syringe programs (NSPs) have proven to be effective and moderately effective in preventing transmission of HCV infection and minimizing drug-related harms among people who inject ...

Short-Duration Treatment Regimens for HCV

The high cost of DAA-based regimens remains an ethical issue and an obstacle to treatment accessibility. Shorter treatment regimens may offer substantial cost savings, improved ...

Treatment Challenges for Genotype 3 HCV

Data have shown patients with genotype 3 HCV have faster progression of fibrosis and higher rates of cirrhosis, severe steatosis, and hepatocellular carcinoma.

Hepatocellular Carcinoma: Treatment Challenges

Despite continual efforts aimed at finding new treatment options, HCC still has a very low 5-year survival rate, less than 20%, as many patients are ...

Hepatitis B: Current State of Affairs

One of the main challenges in managing and controlling hepatitis B infection today is identifying people who are infected and ensuring that they have access ...

Latest News

Maternal Use of TDF Does Not Further Reduce HBV Transmission

Maternal Use of TDF Does Not Further Reduce HBV Transmission

Maternal use of tenofovir disoproxil fumarate does not lower hepatitis B virus transmission rates.

BMI Linked to Hepatocellular Carcinoma Risk in Chronic Hepatitis B Virus

BMI Linked to Hepatocellular Carcinoma Risk in Chronic Hepatitis B Virus

For patients with chronic HBV, BMI is significantly associated with increased risk of hepatocellular carcinoma.

Hepatitis C Screening Increasing Among Baby Boomers

Hepatitis C Screening Increasing Among Baby Boomers

Future research should develop interventions to increase HCV screening with special focus on groups demonstrating significantly lower screening rates, such as Hispanics and women.

Accelerated Cortical Aging With Alcohol Dependence in HCV-Infected Individuals

Accelerated Cortical Aging With Alcohol Dependence in HCV-Infected Individuals

Alcohol dependence has deleterious effects on frontal cortical volumes that are compounded by hepatitis C virus infection and drug dependence.

Hepatitis C Eradication With DAAs Improves Carotid Atherosclerosis

Hepatitis C Eradication With DAAs Improves Carotid Atherosclerosis

HCV eradication by DAA improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.

Hepatitis B Virus Treatments

Hepatitis B Usual Dosing Chart

ACIP Votes in Favor of Heplisav-B for Hepatitis B Prevention in Adults

ACIP Votes in Favor of Heplisav-B for Hepatitis B Prevention in Adults

The FDA approval of Heplisav-B was based on data from 3 phase 3 noninferiority trials involving close to 10,000 adults who received the vaccine.

Hepatitis C Virus Treatments

Hepatitis C Virus Infection dose chart with characteristics of patients for whom therapy is widely accepted.

Case of Psoriasis Remission After Hepatitis C Treatment

Case of Psoriasis Remission After Hepatitis C Treatment

A case of remission of psoriasis after treatment of chronic hepatitis C virus has been described.

Shorter duration of glecaprevir-pibrentasvir effective against hepatitis C virus: The ENDURANCE trials

Both 8 and 12-week regimens of glecaprevir-pibrentasvir were highly efficacious in producing sustained virologic response in patients infected with hepatitis C virus genotypes 1 and 3, and the 8-week treatment duration was noninferior to 12-week duration.

Sign Up for Free e-newsletters